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ABSTRACT
THE INFLAMMASOME IN ACUTE MYOCARDITIS
By Harsha Ramanujam Kannan, BS
A thesis submitted in partial fulfillment of the requirements for the degree of Master
of Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2013.
Sponsor: Antonio Abbate, MD, PhD, Department of Internal Medicine
Acute myocarditis is an acute inflammatory syndrome characterized by myocardial
damage and dysfunction often due to a viral infection followed by a variable development
over time. There are currently no specific treatments and standard treatments for heart
failure are generally applied. The inflammasome is a recently identified macromolecular
structure that occupies a central role in the amplification of the inflammatory response and
promotion of cell death during acute and chronic infections. We hypothesized the
formation of the inflammasome in acute myocarditis. To investigate, samples of patients
were collected from the Cardiomyopathy Registry in Trieste, with 12 cases of biopsyproven myocarditis and 11 cases of autopsy-proven myocarditis stained for major
components of the inflammasome through immunofluorescence; 10 of the 12 (83.3%)
biopsy cases and 8 of the 11 (72.7%) autopsy cases presented formation of the
inflammasome in a variety of cells including resident cells (i.e. cardiomyocytes, endothelial
cells, fibroblasts) and

infiltrating cells (i.e. leukocytes) while varying in intensity and

distribution. Control samples of 5 subjects not presenting with any acute cardiac events
showed no formation of the inflammasome. While further studies should look to elucidate
the correlation of inflammasome-formation and progression of disease, this finding paves
the way for further insight into the pathophysiology of acute myocarditis.

v

INTRODUCTION

ACUTE MYOCARDITIS
Acute myocarditis is an inflammatory disorder of the heart muscle.1 Such definition
covers a long list of clinical conditions in which the heart muscle (myocardium) is
primarily involved in an acute inflammatory response that is not secondary to
myocardial ischemia or toxic injury.1-3 Acute myocarditis refers both to the
pathologic condition and the clinical manifestation (disease).

The causes for this inflammatory response are many and vary from infectious
(primarily viral, but also bacterial) to non-infectious (including ‘allergic’ and
autoimmune).1-3 The variability in etiology is paralleled by a large variability in the
clinical presentation, ranging from asymptomatic to cardiogenic shock and sudden
death.1-3

What is common to all these conditions is the presence of (a) myocardial injury +
(b) an ensuing inflammatory response. The manifestation and severity of the
disease is dependent on (a) and (b) and involves the intensity and nature of the
injury and the response (Figure 1).1-4

As such, acute myocarditis involves both cardiomyocyte dysfunction as a result of
the initial virally mediated event as well as tissue injury due to subsequent immune
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response. The immune-mediated response in reaction to the viral component
leads to myocardial inflammation, necrotic events, and ventricular dysfunction.

The exact incidence and prevalence of myocarditis is unknown.1-3 It is often underrecognized or mis-diagnosed.1-3 This is consequential of the fact that many
affected individuals may be asymptomatic at onset while others may be for the
entire duration of the disease. It is estimated that 10% of patients with unexplained
idiopathic cardiomyopathy, 50% with end-stage heart failure, and approximately
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25% of all heart transplantations are due to myocarditis.5-7 Myocarditis is also
found at autopsy in 5-20% of cases of sudden unexplained deaths in young
adults.8-9 Finally, acute myocarditis mimics acute myocardial infarction and
pericarditis, and while the literature is full of reports, the true incidence is unknown
due to lack of systematic studies.

The natural history of acute myocarditis also shows a wide-spectrum of clinical
variability.1-4 Of patients with acute myocarditis, nearly 50% experience an
improvement, whereas the rest will experience worsening cardiomyopathy and
heart failure.1-4,11-12 The Myocarditis Treatment Trial published in 1995 included
111 patients with biopsy-proven myocarditis and depressed left ventricular ejection
fraction (LVEF, mean 25%).13 Patients had paired echocardiograms over 6 and 12
months and were then followed for 5 years for survival. While there was a mean
improvement in LVEF of approximately 10%, most patients continued to have
depressed LVEF, and the 1-year and 5-year mortality rates were a remarkable
20% and 56% respectively (Figure 2).13 A more recent prospective longitudinal
study enrolling all-comers with biopsy-proven acute myocarditis published in 2012
showed an approximate 5-year mortality of 20%, with patients with lower LVEF
being more likely to die.14 These data show that despite improvements in the
treatment of cardiomyopathy, patients with acute myocarditis are at greatly
increased risk of death, especially if LV function is depressed.
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Acute myocarditis is usually suspected on the basis of the clinical presentation but
the diagnosis requires either confirmation with an endomyocardial biopsy (EMB)
providing tissue for histologic assessment or with cardiac magnetic resonance
which may show a characteristic pattern. Often the diagnosis is also supported by
pertinent negative findings excluding other causes (i.e. ischemia). Pathological
observation of acute myocarditis is defined by a leukocytic infiltrate associated
with cardiomyocyte necrosis (in the absence of ischemia or toxic injury).
Cardiotropic virus detection can be performed by PCR techniques and in situ
hybridization to help identify cell types replicating viral genomes.

At present day, there are no specific treatments for acute myocarditis, and thus
standard treatments for heart failure are generally applied. The Myocarditis
Treatment Trial randomized patients to immunosuppressive therapy with
4

prednisone with cyclosporine or azathioprine for 6 months but failed to show an
improvement in LVEF or survival (Figure 2).13 A recent meta-analysis of clinical
trials showed similar results on outcomes despite a small effect on LVEF.15
Immunosuppressive treatment sees a more liberal use in Europe but is reserved to
few specific cases in the USA.1-4 Antiviral treatment revolves around interferon-β
and interferon (IFN)-α2 therapy, which in animal studies has shown to protect
cardiomyocytes against injury and decrease inflammatory cell infiltrates. However,
only IFN-β showed effective clearance of the viral load. Initial studies with
treatment with IFN-β in selected patients with myocardial enteroviral or adenoviral
persistence and LV dysfunction has shown to eliminate the viral genomes in those
patients exhibiting these conditions and lead to improved LV function.3

Specific risk stratification tools are also lacking in acute myocarditis. The
commonly explored markers of immunopathology have failed to show a clear
prediction in patients with biopsy-proven myocarditis.9 Similarly novel methods of
detection have shown frequent presence of viral genome in biopsies16 but have
failed to link a specific virus or the persistence of genome over time with
prognosis.17-18 In some, but not all studies, lack of viral genome and presence of
autoantibodies predicted response to treatment.19-20.

The pathophysiologic mechanisms leading to successful healing and restitution ad
integrum in some cases, or with impaired healing, fibrosis, and cardiomyopathy in
others, are poorly understood.1-4,20-21. The initial injury often involves an infection
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by a virus or intracellular bacterium. These cardiotrophic infectious pathogens
determine an initial injury by replication within the cardiomyocytes. The cellular
injury induces an inflammatory response characterized by an acute infiltrate of
leukocytes to the heart primarily consisting of lymphocytes. Cytotoxic lymphocytes
as well as cytotoxic antibodies are involved in the progression of the injury,
whereas regulatory lymphocytes and neutralizing antibodies appear to be involved
in protection

4,20-21

. These factors, however, seem to poorly explain and poorly

predict outcome and treatments directed specifically at lymphocytes (prednisone,
cyclosporine, azathioprine) or autoantibodies (plasma derived immunoglobulins)
have been disappointing.

In conclusion, acute myocarditis is a rather common disease, with an unfavorable
outcome, no specific therapies, poorly understood pathophysiologic mechanisms,
and paucity of clinically useful predictors. It follows that there is an urgent need for
further research in this area. In this study, we addressed the role of a new
pathophysiologic

mechanism

with

potential

prognostication, and therapy.

6

implications

for

diagnosis,

THE INFLAMMASOME
The inflammasome is a recently identified macromolecular structure activated
during cellular and tissue injury that amplifies the inflammatory response.22-23
During infection or injury, pathogen-associated molecular patterns (PAMPs) or
danger-associated molecular patterns (DAMPs) are sensed and lead to the
triggering of the inflammasome. This step has been shown to represent an
essential process in the initiation of the local and systemic inflammatory response
in virtually all forms of infectious or sterile tissue injury. Viral infections are known
to activate the inflammasome and the outcome of the infection is often determined
by this interaction leading to either death of the infected cell (pyroptosis) and virus,
or survival of both cell and virus.24 Hence, while viruses are inducers of the
inflammasome per se, viral proteins may inhibit the inflammasome (“evasion”).24 It
has been recently shown that during sterile ischemic injury to the heart the
inflammasome promotes further damage.25 Others have shown that the same
occurs in other cardiomyopathies.26-28 Yet there has been no report investigating
the inflammasome in acute myocarditis. Understanding the pathophysiology of the
inflammasome formation in the heart during acute myocarditis may provide clues
into the clinical variability of acute myocarditis.

The structure and function of the components of the inflammasome can be
summarized with the presence of a sensor (that directly or indirectly binds PAMPs
or DAMPs), an adaptor (scaffold), and an effector (enzyme).22-23 While there are
several interchangeable sensors, caspase-1 is the common effector protein, and
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defines the inflammasome. Caspase-1 (also called interleukin-1β converting
enzyme) leads to the maturation of key pro-inflammatory cytokines such as
interleukin-1β (IL-1β) and interleukin-18 (IL-18), and induces cell death by
pyroptosis.29 The apoptosis-associated speck-like protein containing a caspase-1
recruiting domain (ASC) is the most common adaptor serving as a scaffold for the
inflammasome specks (visible at light microscopy)(Figures 3-4).22-23,30 Many of the
effects of the inflammasome are mediated by the release of active IL-1β and IL-18.

Recent pharmaceutical developments in this area have further stimulated the
interest in the inflammasome, IL-1β, and IL-18 in many clinical conditions ranging
from rare hereditary diseases related to mutations in inflammasome genes to more
common illnesses like rheumatoid arthritis, gout, and diabetes.31-32 These
disparate conditions have in common the property of being “auto-inflammatory”.33
Great interest in the inflammasome is also evident in the infectious disease
literature especially inherent to virus and bacteria.24,34

We therefore hypothesize that the viral infection or the ensuing cellular destruction
seen during acute myocarditis leads to the formation and activation of the
inflammasome (Figure 3). Identifying a role of the inflammasome would provide an
opportunity to explore inflammasome-related markers for diagnostic or prognostic
purposes. Furthermore inhibitors of IL-1β and IL-18 are available and ready to be
tested, while novel inhibitors are being developed. Recent clinical studies have
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been completed, with 3 pilot clinical trials showing a favorable effect of anakinra
(an IL-1 blocker) in patients with acute myocardial infarction or heart failure.35-37

9

APPROACH

In this study, we investigated the presence of inflammasome in tissue samples
obtained through autopsy or endomyocardial biopsy in patients with acute
myocarditis. These experiments are made possible by the existence of a unique,
well-designed and maintained Cardiomyopathy Registry held in Trieste, Italy, in
which all patients with acute myocarditis are identified and followed prospectively,
and in which heart specimens derived from endomyocardial biopsies or autopsies
are stored for future studies.10,38-42

The Cardiomyopathy Registry in Trieste was started on January 1, 1981 and it is
still current. Between January 1981 and December 2012, the Registry included 98
patients with biopsy-proven myocarditis (or autopsy-proven myocarditis if the
patient deceased before the biopsy). All patients underwent clinical evaluation with
laboratory testing, ECG, ECG Holter, echocardiography, coronary angiogram and
endomyocardial biopsy (with classical pathology analyses). All patients received
standard heart failure treatments according to guidelines, and were followed after
6 and 12 months; those with heart failure symptoms or evidence of abnormal heart
dimensions or function were followed every 6 months up to 48 months.
Endomyocardial biopsies were obtained from the left and right ventricles. Samples
were stored in formalin and then embedded in paraffin for histology and
immunopathology, or snap frozen with liquid nitrogen for identification of viral
genome. Mean age of the patients is 37, with 70% being males. The mortality
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rates at 2 and 5 years were 11% and 17%, respectively. Approximately half of the
patients presented with heart failure, and these were more likely to have
depressed LVEF, with a much lower 5-year transplant-free survival (73%).

We determined the presence of inflammasome aggregates in the different cell
types (cardiomyocytes, leukocytes, fibroblasts, and endothelial cells).

SELECTION OF THE CASES
As explained earlier, acute myocarditis is a heterogeneous syndrome with wide
variability in the modality of onset, severity of illness, cause and prognosis. In
order to select a more homogeneous population for this study, we included 12
cases of patients with acute myocarditis according to the Dallas criteria.43 We
excluded patients with a longer duration of symptoms as well as asymptomatic
patients, as this would limit our insight into the natural history of the disease. We
excluded patients with eosinophilic myocarditis, giant-cell myocarditis, sarcoidosis,
HIV cardiomyopathy, fungal, and protozoal myocarditis, since all these conditions
are uniquely characterized by either a mechanism of disease, a specific and rather
effective therapeutic strategy, or additional morbidities. This provided a rather
homogenous cohort of cases with viral or autoimmune myocarditis of recent onset.
Also included were 11 patients diagnosed at autopsy (fatal cases) for comparison.
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SELECTION OF THE CONTROLS
In order to evaluate the specificity of our findings, we included controls in which,
according to our hypothesis, staining was not expected to present formation of the
inflammasome. Five subjects were enrolled as controls and presented with chronic
cardiac disease but without acute myocarditis or other acute cardiac event who
died and underwent autopsy.

PROCESSING OF THE SAMPLES
The cases were identified in the registry, and the histological slides were prepared
in Trieste, Italy, before being shipped to our laboratory at Virginia Commonwealth
University. The slides were identified with a progressive number and not with the
identity of the subject. The team in Trieste coded the samples in a way that the
investigators in Virginia could not distinguish the identity of the cases.

IDENTIFICATION OF THE INFLAMMASOME IN THE HEART
We employed immunofluorescence staining using antibodies raised against ASC
(Sigma Aldrich, PRS2287, rabbit polyclonal) and caspase-1 (Sigma Aldrich,
C4851, rabbit polyclonal; Novus Biological, 14F468, mouse monoclonal). The
rationale for using ASC or caspase-1 as main markers for the inflammasome is
that although multiple sensors may be involved, the effector caspase-1 and
adaptor protein ASC are by far the most common components of the
inflammasome. Based on our hypothesis, we expected to see inflammasome
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“specks” as peri-nuclear cytoplasmatic aggregates in the majority of heart samples
with differing degrees of intensity and presence in different cell types including
leukocytes, endothelial cells, fibroblasts and cardiomyocytes.

To characterize the cellular pattern we used a double staining technique with
antibodies against S100A4 (Sigma Aldrich, 7493P1, goat polyclonal) and CD31
(Cell Signaling, #3528, mouse monoclonal) to recognize fibroblasts and
endothelial cells respectively, plus cardiac actin (Sigma Aldrich, A9357, mouse
monoclonal) as a marker to denote cardiomyocytes.

STAINING OF THE SAMPLES
Staining of samples occurred over three days, the first of which involved
rehydration of samples, antigen retrieval, and application of primary antibody for
ASC or caspase-1. Samples were taken through three changes of xylene, 5
minutes each, two changes of 100% ethanol, and changes through 95% and 70%
ethanol for a minute each before being placed in running tap water to remove
paraffin embedding and rehydrate. Antigen retrieval was performed using a
steamer with samples placed in 0.01M citrate buffer pH 6.0 for 20 minutes.
Blocking to minimize non-specific binding used 1% normal donkey serum in PBS
for 15 minutes. Application of primary antibody diluted 1:50 (ASC or caspase-1) in
PBS was left to incubate overnight in 4°C.
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Second day involved washing samples of the primary before application of
fluorescence-conjugated secondary antibody diluted 1:100 in PBS incubated for
four hours at room temperature. The second primary antibody, marking cell type,
was diluted 1:100 in PBS, applied, and left to incubate overnight (4°C). The
secondary antibody of a different fluorescence wavelength was applied and left to
incubate for four hours on the third day (RT).

Autofluorescence due to lipofuscin-like pigments is seen in the heart and central
nervous system.45 The sarcomere may also be a source of autofluorescence.46 To
account for this and ensure distinction of positive staining for only ASC and
caspase-1, we used a solution of 1% Sudan Black in 70% Ethanol for five minutes
following the application of the final secondary antibody, quenching the nonspecific
fluorescence without compromising the signal of the specific antibodies.47 Nuclear
staining was done with 4’,6-diamidino-2-phenylindole (DAPI) 1:1000 for 5 minutes
and samples were cover slipped with a tris-glycerol mounting media.

ASSESSMENT OF THE INFLAMMASOME IN THE HEART
All the final images of samples were acquired with an IX70 microscope and
cellSens Dimension digital imaging software (both Olympus) using a 40x objective
(400x magnification). Filter sets from the software for each separate fluorescenceconjugated antibody were layered to render a color composite image.
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Observation of “specks” was counted and categorized by cell type (cardiomyocyte,
non-cardiomyocyte residents, and leukocytes) per field of view (40x).

STATISTICAL ANALYSIS
All data are presented as median and interquartile range; non-parametric tests
were used because of a potential deviation from a Gaussian distribution. The
SPSS statistical package 19.0 was used. The Mann-Whitney test was used to
compare continuous variables between 2 different groups (i.e. cases vs controls),
the Wilcoxon test was used to compare paired variables within one given group
(i.e. necrotic region vs remote region of the heart), the Spearman rank test was
used to define correlation between two variables (i.e. inflammasome specks and
left ventricular ejection fraction). For each measurement, the effect we were
interested in detecting was 2SDs from control. Therefore, a sample size of 6 in
each group had a 80% power to detect an effect size of δ=|µ1-µ2|/σ=2 using an
estimate from a t-test (2-sided, α=0.05). Multiple comparisons reduces the
accuracy; as such we maintained a target P<0.05 for this phase with the
understanding that validation will be required.
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RESULTS

In this preliminary phase we studied 12 patients with biopsy-documented acute
myocarditis deriving, 11 cases in which the diagnosis of fatal acute myocarditis
was made post-mortem, and 5 cases of patients affected by chronic heart disease
but not of acute cardiac issues selected at autopsy, also in Trieste.

Formation of the inflammasome was detected using immunofluorescence for ASC,
the scaffold protein that appears as an aggregate, speck(s), during inflammasome
formation (Figure 4-7). Confirmation was made by colocalization of ASC and
effector caspase-1, definitive of the inflammasome (Figure 8-10).

The inflammasome was detected in the heart in 10 of 12 cases (83.3%) of biopsyproven myocarditis as well as in 8 of 11 cases (72.7%) of post-mortem diagnosis.
Five cases of non-myocarditis samples showed no presence of the inflammasome.
In all but 3 cases of post-mortem diagnosis and 2 cases of biopsy-proven
myocarditis, few inflammasome specks (median 2, range 1-5) per high power field
(HPF, x40) were seen, and mostly in cardiomyocytes, endothelial cells, or
fibroblasts. Two cases of fatal myocarditis showed intense staining for the
inflammasome (30-40 per HPF), mostly in the leukocytes (Figure 11).
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Figure 4. ASC-cardiac actin co-staining in immunofluorescence. ASC (red)
conjugated with Alexa Fluor 594, cardiac actin (green) with Alexa Fluor 488, and
nuclear staining (blue) with DAPI. White arrows point to ASC-positive infiltrating
cells (e.g. leukocytes). Black arrow points to ASC-positive cardiomyocyte. Bottom
panel illustrates staining of a control sample with no acute cardiac events.
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Figure 5. ASC-cardiac actin co-staining in cardiomyocytes. Panels shows a
cardiomyocyte positive for ASC (red) and cardiac actin staining (green), with
nuclear staining by DAPI (blue).
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Figure 6. ASC-caveolin co-staining in endothelial cells. Panels show
endothelial cells positive for ASC (red) and caveolin (green), with nuclear staining
by DAPI (blue).
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Figure 7. ASC-S100A4 co-staining in fibroblasts. Panels shows fibroblasts
positive for ASC (red) and S100A4 (green), with nuclear staining by DAPI (blue).
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We used co-localization of ASC and caspase-1 to determine the presence of
aggregates. The specific antibody used for caspase-1, however, recognized both
the pro-form and cleaved form of caspase-1; hence observation of pro-caspase-1
was seen also to be constitutive in endothelial cells and leukocytes, independent
of ASC expression.

Figure 8. ASC-caspase-1 co-staining. Panels show co-localization (yellow) of
ASC (red) and caspase-1 (green), with nuclear staining by DAPI (blue).
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Figure 9. ASC-caspase-1 co-staining. Panels show co-localization (yellow) of
ASC (red) and caspase-1 (green), with nuclear staining by DAPI (blue).
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Figure 10. ASC-caspase-1 co-staining. Panels show co-localization (yellow) of
ASC (red) and caspase-1 (green), with nuclear staining by DAPI (blue).
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Figure 11. Quantitative assessment of total number of ASC+ cells per field of
image (40x magnification). Averages were taken across 5 images collected from
each sample and plotted. ASC+ cell count per field (40x magnification) expressed
as median and inter-quartile range per cell category divided by biopsy and autopsy
samples, and control samples.
24

DISCUSSION

Acute myocarditis remains a poorly understood pathology, with minimal elucidation
of the mechanism of action and subsequent deficiency of specific therapies
leading to a critical outcome. Herein we present a potential new therapeutic target
in the form of the macromolecular complex inflammasome.

Myocarditis can be infectious in origin or non-infectious. Viral infection and
subsequent activation of the inflammasome has been studied in previous years.50
Antiviral immunity has been linked to three distinct inflammasomes: the NLRP3
inflammasome, RIG-1 inflammasome, and AIM2 inflammasome. These variants all
involved the adaptor protein apoptosis-associated speck-like protein containing a
CARD, or ASC, as a link between the sensor and pro-form of caspase-1 that
ultimately leads to cleavage of pro-inflammatory cytokines IL-1β and IL-18. The
active forms of these cytokines are coupled to observation of infection,
inflammation, and autoimmune processes.50 It followed that the likelihood of
inflammasome formation in acute myocarditis with viral origin was high, a
phenomenon previously left unstudied.

Samples collected biopsy or autopsy of patients confirmed to have myocarditis
were delivered from the Cardiomyopathy Registry in Trieste. Tissues were
embedded in paraffin for preservation. Due to the restrictive nature of sample
arrangement, most appropriate approach was to utilize immunofluorescence
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staining. Previous studies have demonstrated this approach to be a viable and
reliable method of assessment.25

Upon staining, the presence of the scaffold protein ASC was seen in varying
degrees of both intensity and distribution (Figure 4) in cardiomyocyte, fibroblast,
and endothelial cells (Figure 5-7) as well as in non-resident infiltrating cells (i.e.
leukocytes). As an instrumental component of the inflammasome complex, ASC+
staining suggested the presence of the inflammasome in the cases of myocarditis
and not in controls.

ASC+ staining in different cell types demonstrated the presence of the
inflammasome in a wide array of cells. Using caspase-1 staining we confirmed the
presence of another essential component of the inflammasome necessary for proinflammatory cytokine cleavage.

To confirm the incidence of the inflammasome, co-staining for ASC and caspase-1
was conducted for observation of the aggregates in relation to each other – colocalization indicated formation of the aggregates (Figure 8-10).

For comparison that the observations seen were unique to those with myocarditis,
samples from patients with no acute cardiac issues were stained for ASC.
Negative staining in these control subjects indicated that ASC (and the
inflammasome) are not expressed in the heart, in absence of injury (Figure 11).
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What remains is observation of the progression of myocarditis and end-stage
result in linkage with inflammasome presence and activity.

The pathophysiologic role of the inflammasome in acute myocarditis is however
unclear. Further studies are needed to determine whether the intensity of the
inflammasome shows correlation to severity of illness at presentation and/or with
progression to the cardiomyopathy. If the intensity of the inflammasome should
correlate only with the severity of illness initially but remain inconclusive for
prediction or is not determinant of clinical progression, inflammasome-targeted
strategies could be directed selectively towards patients with hemodynamically
unstable acute myocarditis with a high risk of death acutely but potentially
favorable recovery with survival (fulminant myocarditis). If the inflammasome
intensity should not correlate with the severity of the disease or should relate to
even a milder form of the disease, this could suggest that the inflammasome is a
protective phenomenon (i.e. virus clearance).24,34 In this event, it suggests the use
of inflammasome-related therapies (i.e. IL-1β/IL-18) to favor healing. If further
findings suggest the inflammasome in myocarditis to follow the current paradigm –
that is the inflammasome as an adverse remodeling agent in the heart – it follows
that classifying the inflammasome (i.e. particular sensor: NLRP3 vs RIG-1 vs
AIM2) will be greatly beneficial in adding another target of therapy in addition to
currently existing modes of treatment.35-37

27

Still it stands that inhibition of the inflammasome may present itself as a potentially
“double-edged sword.” If inhibition of inflammasome should lead to a weakened
myocardium following injury, it stands that inflammasome disruption will not be an
effective method of treatment, and perhaps inhibition of the products of the
inflammasome, i.e. Interleukin-1β may be preferable.51 In experimental acute
myocardial infarction, selective blockade of IL-1β protects the heart from apoptosis
and ameliorates remodeling without intervening in formation of the active
inflammasome, inhibiting tissue inflammatory response, or disturbing infarct
healing following AMI.51 Its relevance here is the suggestion that IL-1β blockade
does not impair tissue response in such conditions as microbial infections.
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CONCLUSIONS

This study shows for the first time the presence of the inflammasome in the heart
of patients with myocarditis. This study identifies a potential new pathophysiologic
mechanism in acute myocarditis opening the way to improved understanding and
potential improved prognostic stratification and treatment of the disease.

The inflammasome was seen in the heart in 78% of samples with an intensity
ranging from mild to intense. The pathophysiologic role of the inflammasome
formation in the heart during acute myocarditis is however unknown. The next step
will be to accurately quantify the intensity of the formation of the inflammasome
and analyze for the presence of statistical correlations with the clinical
characteristics of the patients or the outcomes.

As of 2013, acute myocarditis remains a poorly understood disease with
unacceptably high morbidity and mortality rates. Identifying an effective and safe
anti-inflammatory therapy for acute myocarditis represents, therefore, an urgent
unmet medical need. Therapies directed at IL-1β and IL-18 (products of the
inflammasome) are already being tested in clinical trials for non-cardiac as well as
cardiac diseases (other than myocarditis), and novel specific inflammasome
inhibitors (small molecules) are being developed.
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We can foresee 3 main possible outcomes: 1) the intensity of the inflammasome
correlates with the severity of illness at presentation and with progression to the
cardiomyopathy – this would support studying inflammasome-targeted treatment;
2) the intensity of the inflammasome correlates with the severity of illness initially
but does not predict clinical progression – this would support studying
inflammasome-targeted strategies in selected patients with hemodynamically
unstable acute myocarditis who have a high risk of death acutely yet if they survive
have a more favorable recovery; 3) the inflammasome does not correlate with the
severity of the disease or even associates with a milder form of the disease – this
would suggest a protective role of the inflammasome (i.e. virus clearance)24,34 and
suggest the use of inflammasome-related therapies (i.e. IL-1β/IL-18) to favor
healing.
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